https://www.selleckchem.com/pr....oducts/tolebrutinib-
81 (1.28-2.55), 1.59 (1.03-2.44) and 2.09 (1.22-3.6 respectively. Compared with TZD nonusers, rosiglitazone users had significantly higher aHR [1.67 (1.26-2.2] and pioglitazone users had no significant difference of aHR [1.12 (0.90-1.64)]. All-cause mortality, hepatocellular carcinoma, decompensated cirrhosis and hepatic failure risks did not differ significantly between TZD users and nonusers. Compared with nonuser, TZD users demonstrated significantly higher MACE risks. Therefore, the risks of cardiovascular complic
Aimer
Commentaire
Partagez
